Our approach – Abcam Limited

Partnering

Your partner from bench to clinic

Fostering strategic partnerships that support the advancement of research, drug discovery, diagnostic development and commercialization.

We offer multiple routes to access best-in-class reagents and tools.

Leveraging our proprietary product portfolio and development platforms we co-create customised products to our partners’ specification.

In addition, by maintaining control over manufacturing and intellectual property of products developed through our in-house platform, our partner’s products benefit from long term patent-protection and access to consistent and high-quality reagents and tools.

Benefits of partnering with us

Off-the-shelf products

High-quality proteomic tools including antibodies, assays, engineered cell lines, available at scale

Customized approach

Leverage our innovative discovery platforms and manufacturing expertise to enable the co-creation of new precision reagents

Expert teams

Reagent discovery, development, formulation and manufacturing and project management

IP protection

Strong product IP protection ensuring a proprietary position

Global sales and commercialization

Global sales and commercialization channel to support accelerated market acceptance of promising products

Seeking partnerships

Abcam has several key areas of interest where we are looking for partnerships:

Commercial partnerships to advance diagnostic and therapeutic discovery

We are interested in partnering with companies or organisations developing either novel clinical or instrument platforms or upgrading their existing platforms to address novel biomarkers. Abcam will help these partners develop the right content, such as antibodies and other protein reagents or assays, to meet the demanding needs of their users.

Product and technology partnerships

As we strive to provide the highest quality and most relevant antibodies to researchers around the world, we are seeking opportunities to in-license certain assets to directly expand our portfolio. Furthermore, we are searching for partnerships to enhance our recombinant antibody development capabilities.

Specifically we are seeking the following:

Monoclonal and recombinant antibodies and antibody platform technologies
Gene-edited cell lines where Abcam provides a streamlined process to address CRISPR blocking IP
Conjugation technologies including chemistries, labels, dyes and other enabling technologies
Artificial intelligence technologies to enhance development of recombinant antibodies
Cellular assays focused on areas such as metabolism, kinases, GPCRs, and broad platform technologies
Organoid and IPSc technologies and products

Investment opportunities

Where there is an immediate, mutually beneficial commercial opportunity, we also invest in early stage companies, and university spin outs developing technologies in the following areas: